Literature DB >> 21282454

Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy.

Pere Domingo1, M Carmen Cabeza, Alain Pruvost, Ferran Torres, Juliana Salazar, M del Mar Gutierrez, M Gracia Mateo, Angels Fontanet, Irene Fernandez, Joan C Domingo, Francesc Villarroya, Francesc Vidal, Montserrat Baiget.   

Abstract

The antiviral activity and toxicity of stavudine (d4T) depend on its triphosphate metabolite, stavudine triphosphate (d4T-TP). Therefore, modifications in intracellular levels of d4T-TP may change the toxicity profile of stavudine. d4T-TP intracellular levels in peripheral blood mononuclear cells were determined with a prominence liquid chromatograph connected to a triple-quadruple mass spectrometer. Polymorphisms in the thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), dihydrofolate reductase (DHFR), reduced folate carrier 1 (RFC1; SLC19A1), and cyclin D1 (CCND1) genes were determined by direct sequencing using an ABI Prism 3100 genetic analyzer or Fluidigm's Biomark system. The Mann-Whitney test, rank analysis of variance (with Bonferroni's adjusted post hoc comparisons), and logistic regression were used for the inferential analyses. Thirty-three stavudine-treated patients were enrolled in this cross-sectional study. d4T-TP intracellular levels were 11.50 fmol/10(6) cells (interquartile range [IQR] = 8.12 to 13.87 fmol/10(6) cells) in patients with a high-expression TS genotype (2/3G, 3C/3G, and 3G/3G), whereas in those with a low-expression TS genotype (2/2, 2/3C, and 3C/3C), they were 21.40 fmol/10(6) cells (IQR = 18.90 to 27.0 fmol/10(6) cells) (P < 0.0001). Polymorphisms in the MTHFR, DHFR, RFC1, and CCND1 genes did not influence the intracellular concentration of d4T-TP. d4T-TP levels were independently associated with the TS genotype (low versus high expression; odds ratio [OR] = 86.22; 95% confidence interval [CI] = 8.48 to nonestimable; P = 0.0023). The low-expression TS genotype was associated with the development of HIV/highly active antiretroviral therapy-associated lypodystrophy syndrome (HALS) (OR = 14.0; 95% CI = 2.09 to 108.0; P = 0.0032). Our preliminary data show that polymorphisms in the thymidylate synthase gene are strongly associated with d4T-TP intracellular levels and with development of HALS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21282454      PMCID: PMC3067160          DOI: 10.1128/AAC.01589-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

1.  END-PRODUCT INHIBITION OF THYMIDINE KINASE ACTIVITY IN NORMAL AND LEUKEMIC HUMAN LEUKOCYTES.

Authors:  E BRESNICK; R J KARJALA
Journal:  Cancer Res       Date:  1964-06       Impact factor: 12.701

Review 2.  Pyrimidine pathways in health and disease.

Authors:  Monika Löffler; Lynette D Fairbanks; Elke Zameitat; Anthony M Marinaki; H Anne Simmonds
Journal:  Trends Mol Med       Date:  2005-09       Impact factor: 11.951

3.  Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia.

Authors:  Margalida Rotger; Patrick Taffe; Gabriela Bleiber; Huldrych F Gunthard; Hansjakob Furrer; Pietro Vernazza; Henning Drechsler; Enos Bernasconi; Martin Rickenbach; Amalio Telenti
Journal:  J Infect Dis       Date:  2005-09-09       Impact factor: 5.226

4.  Molecular genetic analysis of the human dihydrofolate reductase gene: relation with plasma total homocysteine, serum and red blood cell folate levels.

Authors:  Henkjan Gellekink; Henk J Blom; I J M van der Linden; Martin den Heijer
Journal:  Eur J Hum Genet       Date:  2006-09-13       Impact factor: 4.246

5.  Direct determination of phosphorylated intracellular anabolites of stavudine (d4T) by liquid chromatography/tandem mass spectrometry.

Authors:  A Pruvost; F Becher; P Bardouille; C Guerrero; C Creminon; J F Delfraissy; C Goujard; J Grassi; H Benech
Journal:  Rapid Commun Mass Spectrom       Date:  2001       Impact factor: 2.419

6.  Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens.

Authors:  Pere Domingo; Maria Carmen Cabeza; Alain Pruvost; Juliana Salazar; Maria Del Mar Gutierrez; Maria Gracia Mateo; Joan C Domingo; Irene Fernandez; Francesc Villarroya; Jessica Muñoz; Francesc Vidal; Montserrat Baiget
Journal:  Clin Infect Dis       Date:  2010-04-01       Impact factor: 9.079

7.  Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

Authors:  David W Haas; Laura M Smeaton; Robert W Shafer; Gregory K Robbins; Gene D Morse; Line Labbe; Grant R Wilkinson; David B Clifford; Richard T D'Aquila; Victor De Gruttola; Richard B Pollard; Thomas C Merigan; Martin S Hirsch; Alfred L George; John P Donahue; Richard B Kim
Journal:  J Infect Dis       Date:  2005-11-01       Impact factor: 5.226

8.  A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity.

Authors:  I Weisberg; P Tran; B Christensen; S Sibani; R Rozen
Journal:  Mol Genet Metab       Date:  1998-07       Impact factor: 4.797

Review 9.  C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.

Authors:  Elena De Mattia; Giuseppe Toffoli
Journal:  Eur J Cancer       Date:  2009-01-12       Impact factor: 9.162

10.  Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools.

Authors:  Jennifer E Vela; Michael D Miller; Gerald R Rhodes; Adrian S Ray
Journal:  Antivir Ther       Date:  2008
View more
  6 in total

Review 1.  Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.

Authors:  Maxwell O Akanbi; Kimberly K Scarsi; Kimberly Scarci; Babafemi Taiwo; Robert L Murphy
Journal:  Expert Opin Pharmacother       Date:  2012-01       Impact factor: 3.889

2.  Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.

Authors:  Sherwin K B Sy; Ruben Malmberg; Aoi Matsushima; Eduardo Asin-Prieto; Bernd Rosenkranz; Mark F Cotton; Hartmut Derendorf; Steve Innes
Journal:  Int J Antimicrob Agents       Date:  2015-01-19       Impact factor: 5.283

3.  Delimiting Allelic Imbalance of TYMS by Allele-Specific Analysis.

Authors:  Emilia Balboa-Beltrán; Raquel Cruz; Angel Carracedo; Francisco Barros
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

Review 4.  Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.

Authors:  Zaikuan J Yu; Eric P Mosher; Namandjé N Bumpus
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-09-22       Impact factor: 13.820

5.  Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapy.

Authors:  Pere Domingo; Maria del Carmen Cabeza; Ferran Torres; Juliana Salazar; Maria del Mar Gutierrez; Maria Gracia Mateo; Esteban Martínez; Joan Carles Domingo; Irene Fernandez; Francesc Villarroya; Esteban Ribera; Francesc Vidal; Montserrat Baiget
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

6.  Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40∶01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients.

Authors:  Pere Domingo; Maria Gracia Mateo; Alain Pruvost; Ferran Torres; Juliana Salazar; Maria Del Mar Gutierrez; Joan Carles Domingo; Irene Fernandez; Francesc Villarroya; Francesc Vidal; Montserrat Baiget; Oscar de la Calle-Martín
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.